LGND
NASDAQLigand Pharmaceuticals Incorporated
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$295.52-1.29 (-0.43%)
2026-07-162026-10-16
News · 26 weeks68-82%
2026-04-262026-10-18
Mix2590d
- Insider7(28%)
- SEC Filings6(24%)
- Other5(20%)
- Analyst3(12%)
- Earnings3(12%)
- M&A1(4%)
Latest news
25 items- PRLigand to Report Third Quarter 2026 Financial Results on October 29, 2026JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, October 29, 2026 Time:8:30 a.m. Eastern time Conference Call:United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 708822080 Webcast:Live and replay webcasts of the call are available here. About LigandLigand is a le
- INSIDERSEC Form 4 filed by Ligand Pharmaceuticals Incorporated4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- ANALYSTBarclays initiated coverage on Ligand Pharma with a new price targetBarclays initiated coverage of Ligand Pharma with a rating of Overweight and set a new price target of $345.00
- INSIDERDirector Zimmermann Martine covered exercise/tax liability with 115 shares, decreasing direct ownership by 3% to 3,782 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 MillionJUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales
- PRSydnexis Announces Royalty Agreement with Ligand for Ryjunea®$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance SYD-101 through U.S. regulatory process and prepares for potential commercialization in 2027 Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand
- PRPrimrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersSAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors. The proceeds will help Primrose continue to expand the reach and capabilities of its different
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 MillionRyjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s ("Santen") Ryjunea® from Sydnexis, Inc. ("Sydnexis") for a $23 million upfront payment. Ryjunea is a once-nightly, low-dose atropine eye drop designed to slow progression of myopia (commonly known as nearsighte
- INSIDERDirector Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERCLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECAmendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand to Participate in September Investor ConferencesJUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and a
- INSIDERChief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- ANALYSTLeerink Partners initiated coverage on Ligand PharmaLeerink Partners initiated coverage of Ligand Pharma with a rating of Outperform
- PROrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both the AVIM Therapy and Virtue SAB programs. NEW HOPE, Pa., Aug. 10, 20
- SECSEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Reports Second Quarter 2026 Financial ResultsSecond quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "Ligand delivered another strong quarter, with royalty revenue growing 32% year-over-year and continue
- INSIDERCLO & Secretary Reardon Andrew sold $1,444,951 worth of shares (5,000 units at $288.99) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- PRLigand to Report Second Quarter 2026 Financial Results on August 6, 2026JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, August 6, 2026 Time:8:30 a.m. Eastern time Conference Call:United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 780702347 Webcast:Live and replay webcasts of the call are available here. About LigandLigand is a leadi
- SECSEC Form S-8 filed by Ligand Pharmaceuticals IncorporatedS-8 - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- ANALYSTCitigroup resumed coverage on Ligand Pharma with a new price targetCitigroup resumed coverage of Ligand Pharma with a rating of Buy and set a new price target of $387.00
LGND FAQ
6 questionsWhat does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled...Where does LGND stock trade?
Ligand Pharmaceuticals Incorporated (LGND) is listed on NASDAQ.What sector and industry is LGND in?
Ligand Pharmaceuticals Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LGND?
Ligand Pharmaceuticals Incorporated has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-09-25.What companies are similar to LGND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LGND side-by-side with any of them on Quantisnow.How can I track LGND on Quantisnow?
Quantisnow aggregates Ligand Pharmaceuticals Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGND to receive live email and push alerts on every new disclosure.